14.	Equity Plans and Stock-Based Compensation

Stock Plans

Under the 2004 Stock Incentive Plan (“2004 Plan”) options to purchase 77,774 shares of common stock remained outstanding as of December 31, 2017.

Under the 2010 Employment Inducement Award Plan (“2010 Inducement Plan”) options to purchase 11,450 shares of common stock remained outstanding as of December 31, 2017.

The 2011 Equity Incentive Plan (“2011 Plan”) was approved by the Company’s stockholders and adopted in January 2011. On June 2, 2017, the stockholders of the Company approved an amendment and restatement of the 2011 Plan to increase the number of shares of common stock authorized for issuance under the plan by 1,600,000. The 2011 Plan, as amended, provides for the issuance of up to 10,343,442 shares of our common stock to employees and non-employees of the Company. The 2011 Plan is administered by our Board of Directors, or a designated committee of the Board of Directors, and awards granted under the 2011 Plan have a term of 7 or 10 years unless earlier terminated by the Board of Directors. As of December 31, 2017, options to purchase 3,373,555 shares of common stock remained outstanding under the 2011 Plan. As of December 31, 2017, there were 2,100,333 shares of common stock reserved for issuance under the 2011 Plan.

On November 28, 2017, the Company adopted the Dynavax Technologies Corporation Inducement Award Plan (the “2017 Inducement Plan”), pursuant to which the Company reserved 1,200,000 shares of its common stock for issuance under the 2017 Inducement Plan to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual’s entry into employment with the Company within the meaning of Nasdaq Listing Rule 5635(c)(4). As of December 31, 2017, there were 1,125,200 shares of common stock reserved for issuance under the 2017 Inducement Plan.

Activity under our stock plans is set forth below:

	Shares Underlying Outstanding Options (in thousands)			Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Balance at December 31, 2016		3,975		$	21.38
Options granted		535			12.23
Options exercised		(144	)		14.28
Options cancelled:
Options forfeited (unvested)		(400	)		18.30
Options cancelled (vested)		(411	)		30.78
Balance at December 31, 2017		3,555		$	19.56		6.04	$	7,477
Vested and expected to vest at December 31, 2017		3,533		$	19.56		6.04	$	7,468
Exercisable at December 31, 2017		2,294		$	21.35		5.77	$	2,702

The total intrinsic value of stock options exercised during the years ended December 31, 2017, 2016 and 2015 was $0.9 million, $0.2 million and $0.4 million, respectively. The total intrinsic value of exercised stock options is calculated based on the difference between the exercise price and the quoted market price of our common stock as of the close of the exercise date.

The total fair value of stock options vested during the years ended December 31, 2017, 2016 and 2015 was $13.0 million, $12.1 million and $6.9 million, respectively.

Our non-vested stock awards are comprised of restricted stock units granted with performance and time-based vesting criteria. A summary of the status of non-vested restricted stock units as of December 31, 2017, and activities during 2017 are summarized as follows:

	Number of Shares (In thousands)			Weighted-Average Grant-Date Fair Value
Non-vested as of December 31, 2016		699		$	12.12
Granted		2,217			5.34
Vested		(188	)		18.24
Forfeited		(285	)		7.74
Non-vested as of December 31, 2017		2,443		$	6.01

Stock-based compensation expense related to restricted stock units was approximately $5.5 million for the year ended December 31, 2017. The aggregate intrinsic value of the restricted stock units outstanding as of December 31, 2017, based on our stock price on that date, was $45.7 million.

The weighted average grant-date fair value of restricted stock units granted during the years ended December 31, 2017, 2016 and 2015 was, $5.34, $12.42 and $20.05, respectively. The total fair value of restricted stock units vested during the years ended December 31, 2017, 2016 and 2015 was $1.2 million, $1.0 million and $0.1 million, respectively.

Stock-Based Compensation

Under our stock-based compensation plans, option awards generally vest over a four-year or three-year period contingent upon continuous service and unless exercised, expire seven or ten years from the date of grant (or earlier upon termination of continuous service). The Company has also granted performance-based equity awards to certain of our employees under the 2017 Inducement and 2011 Plans. As of December 31, 2017, approximately 60,000 shares were outstanding related to options and restricted stock units subject to these performance-based vesting criteria. The fair value of each option is estimated on the date of grant using the Black-Scholes option valuation model and the following weighted-average assumptions:

	Stock Options									Employee Stock Purchase Plan
	Year Ended December 31,									Year Ended December 31,
	2017			2016			2015			2017			2016			2015
Weighted-average fair value	$	8.27		$	9.54		$	13.37		$	3.05		$	7.86		$	9.18
Risk-free interest rate		1.9	%		1.4	%		1.7	%		1.0	%		0.6	%		0.4	%
Expected life (in years)		4.5			4.9			5.9			1.2			1.2			1.2
Expected Volatility		0.9			0.7			0.7			1.0			0.6			0.6

Expected volatility is based on historical volatility of our stock price. The expected life of options granted is estimated based on historical option exercise and employee termination data. Our senior management, who hold a majority of the options outstanding, and other employees were grouped and considered separately for valuation purposes. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. Forfeiture estimates are based on historical employee turnover. The dividend yield is zero percent for all years and is based on our history and expectation of dividend payouts.

Compensation expense is based on awards ultimately expected to vest and reflects estimated forfeitures. For equity awards with time-based vesting, the fair value is amortized to expense on a straight-line basis over the vesting periods. For equity awards with performance-based vesting criteria, the fair value is amortized to expense when the achievement of the vesting criteria becomes probable.

We recognized the following amounts of stock-based compensation expense (in thousands):

	Year Ended December 31,
	2017		2016		2015
Employees and directors stock-based compensation expense	$	14,917	$	14,126	$	9,316

	Year Ended December 31,
	2017		2016		2015
Research and development	$	7,827	$	6,742	$	4,123
Selling, general and administrative		7,090		7,384		5,193
Total	$	14,917	$	14,126	$	9,316

In addition, the cash-settled portion of stock compensation expense was $0.6 million and $0.4 million for the years ended December 31, 2016 and 2015, respectively. No cash-settled portion of stock compensation expense was incurred during 2017.

As of December 31, 2017, the total unrecognized compensation cost related to non-vested stock options and awards deemed probable of vesting, including all stock options with time-based vesting, net of estimated forfeitures, amounted to $21.3 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.7 years. Additionally, as of December 31, 2017, the total unrecognized compensation cost related to equity awards with performance-based vesting criteria amounted to $0.3 million.

Employee Stock Purchase Plan

The 2014 Employee Stock Purchase Plan, as amended, (the “Purchase Plan”) provides for the purchase of common stock by eligible employees and became effective on May 28, 2014. The purchase price per share is the lesser of (i) 85% of the fair market value of the common stock on the commencement of the offer period (generally, the sixteenth day in February or August) or (ii) 85% of the fair market value of the common stock on the exercise date, which is the last day of a purchase period (generally, the fifteenth day in February or August). For the year ended December 31, 2017, employees have acquired 84,247 shares of our common stock under the Purchase Plan and 98,227 shares of our common stock remained available for future purchases under the Purchase Plan.

As of December 31, 2017, the total unrecognized compensation cost related to shares of our common stock under the Purchase Plan amounted to $0.4 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.2 years.